Xtant Medical Holdings, Inc. (XTNT)

Price$0.46

Value ScoreA

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-44.63%

Price vs S&P 500 (4W)-20.88%

VGM Score55.10

Market Capitalization$64.80M

P/E Ratio (Annual)13.03x

All Metrics

P/CF (Annual)5.17x

Book Value / Share (Quarterly)$0.35

P/TBV (Annual)2.17x

Revenue Growth (3Y)32.20%

Cash Flow / Share (Quarterly)$0.06

Price vs S&P 500 (YTD)-52.01%

Gross Margin (TTM)62.34%

Net Profit Margin (TTM)1.50%

EPS (TTM)$0.01

10-Day Avg Trading Volume0.18M

EPS Excl Extra (TTM)$0.01

Revenue Growth (5Y)20.22%

EPS (Annual)$0.03

ROI (Annual)6.51%

Gross Margin (Annual)62.92%

Net Profit Margin (5Y Avg)-6.60%

Cash / Share (Quarterly)$0.09

P/E Basic Excl Extra (TTM)35.49x

Revenue Growth QoQ (YoY)-36.53%

P/E Normalized (Annual)13.03x

ROA (Last FY)5.28%

Revenue Growth TTM (YoY)-0.32%

EBITD / Share (TTM)$0.08

ROE (5Y Avg)-13.55%

Operating Margin (TTM)5.40%

Cash Flow / Share (Annual)$0.07

P/B Ratio1.33x

P/B Ratio (Quarterly)1.61x

Net Income / Employee (Annual)$32,900

EV / Revenue (TTM)0.53x

Net Interest Coverage (TTM)2.92x

ROA (TTM)1.91%

EV / EBITDA (TTM)5.77x

EPS Incl Extra (Annual)$0.03

Current Ratio (Annual)2.65x

Quick Ratio (Quarterly)1.56x

3-Month Avg Trading Volume0.16M

52-Week Price Return-33.91%

EV / Free Cash Flow (Annual)6.39x

P/E Incl Extra (TTM)35.49x

Revenue / Employee (TTM)$807,300

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)0.48x

Asset Turnover (Annual)1.42x

52-Week High$0.95

Operating Margin (5Y Avg)-3.87%

EPS Excl Extra (Annual)$0.03

CapEx CAGR (5Y)9.04%

Tangible BV CAGR (5Y)29.22%

26-Week Price Return-28.70%

Quick Ratio (Annual)1.55x

13-Week Price Return-20.10%

Total Debt / Equity (Annual)0.50x

Current Ratio (Quarterly)3.34x

Enterprise Value$64.96M

Revenue / Share Growth (5Y)-13.76%

Asset Turnover (TTM)1.28x

Book Value / Share Growth (5Y)14.22%

Revenue / Employee (Annual)$886,900

Inventory Turnover (Annual)1.44x

Pretax Margin (Annual)5.23%

Cash / Share (Annual)$0.12

3-Month Return Std Dev53.25%

Gross Margin (5Y Avg)59.21%

Net Income / Employee (TTM)$12,100

EBITDA CAGR (5Y)64.07%

EBITDA Interim CAGR (5Y)45.07%

ROE (Last FY)9.76%

Net Interest Coverage (Annual)2.30x

EPS Basic Excl Extra (Annual)$0.03

P/FCF (TTM)6.38x

Receivables Turnover (TTM)6.00x

EV / Free Cash Flow (TTM)8.36x

Total Debt / Equity (Quarterly)0.25x

EPS Incl Extra (TTM)$0.01

Receivables Turnover (Annual)6.96x

ROI (TTM)2.44%

P/S Ratio (TTM)0.53x

Pretax Margin (5Y Avg)-6.61%

Revenue / Share (Annual)$0.89

Tangible BV / Share (Annual)$0.36

Forward P/E45.04x

Price vs S&P 500 (52W)-62.11%

P/E Ratio (TTM)35.49x

Year-to-Date Return-41.07%

5-Day Price Return-3.75%

EPS Normalized (Annual)$0.03

ROA (5Y Avg)-6.90%

Net Profit Margin (Annual)3.71%

Month-to-Date Return-11.71%

Cash Flow / Share (TTM)$0.05

EBITD / Share (Annual)$0.11

Operating Margin (Annual)7.89%

LT Debt / Equity (Annual)0.22x

P/CF (TTM)7.08x

ROI (5Y Avg)-8.27%

P/E Excl Extra (TTM)35.49x

LT Debt / Equity (Quarterly)0.17x

EPS Basic Excl Extra (TTM)$0.01

P/TBV (Quarterly)1.62x

P/B Ratio (Annual)2.15x

Inventory Turnover (TTM)1.30x

Pretax Margin (TTM)3.20%

Book Value / Share (Annual)$0.36

Price vs S&P 500 (13W)-29.84%

Beta-0.20x

P/FCF (Annual)6.38x

Revenue / Share (TTM)$0.87

ROE (TTM)3.68%

52-Week Low$0.44

vGradeA

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.02est. -0.02

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.25

4.22

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
XTNTXtant Medical Holdings, Inc.	A	C	D	$0.46
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

Xtant Medical Holdings develops and commercializes orthobiologics and spinal implant systems for complex spinal fusion, deformity, and degenerative procedures. Its product portfolio includes OsteoSponge, OsteoSelect Plus, OsteoWrap, and 3Demin allografts, sold to orthopedic spine surgeons and neurosurgeons. The company generates the majority of its revenue from the U.S. market.